Ascletis Pharma will not to pursue further clinical testing of its experimental oral therapy ASC42 for adults with primary biliary cholangitis (PBC). The…
News
CHOLESTASIS
NewsNew NR1H4 mutation identified in baby girl with PFIC5
A new mutation in the NR1H4 gene was identified as the cause of progressive familial intrahepatic cholestasis type 5 (PFIC5) in a baby girl…
FATTY LIVER DISEASE
NewsMadrigal CEO: Rezdiffra OK for NASH a ‘watershed moment’
The approval of Rezdiffra (resmetirom) last month in the U.S. as the first ever treatment for nonalcoholic steatohepatitis (NASH), a severe type of…
BILIARY ATRESIA
NewsGirl with biliary atresia spotlighted in 2024 ALF Liver Life Walk
Five-year-old Sadie Sellers, who was born with biliary atresia, is the focus of a fundraising event designed to raise awareness of and funds for…
Technologies to prevent, detect, and treat viral hepatitis have advanced considerably in recent decades, but the number of people dying from these infections continues…
CHOLANGITIS
NewsElafibranor for PBC may become Genfit’s first approved molecule
Elafibranor, an oral molecule under regulatory review as a new second-line treatment for adults with primary biliary cholangitis (PBC), may become the first candidate…
CHOLESTASIS
NewsNonprofit funds research to test for pregnancy complication ICP
A nonprofit group has donated $60,000 to support researchers at Yale University School of Medicine working to expand access to a new test that can…
FATTY LIVER DISEASE
NewsFatty liver disease treatment DD01 gets FDA fast track designation
The U.S. Food and Drug Administration (FDA) has granted fast track designation to DD01 as a potential treatment for a severe manifestation of fatty…
ALAGILLE SYNDROME
NewsPruritus treatment Livmarli should be reimbursable: Canadian panel
A Canadian Agency for Drugs and Technologies in Health (CADTH) committee has recommended that Livmarli (maralixibat) be covered by the country’s publicly funded health…
The U.S. Food and Drug Administration (FDA) has again expanded its approval of Gilead Sciences’ medication Vemlidy (tenofovir alafenamide) for chronic hepatitis B…
Recent Posts
- Clinical trial results support bepirovirsen for hepatitis B
- Vitamin D may help protect against liver damage in those with PBC: Study
- Think smoking only affects your lungs? Your liver would like a word.
- Low vitamin D in early pregnancy tied to ICP risk, if fetus is a girl
- This year, my son with Alagille will hit 2 major childhood milestones